Table 3:
Demographic, clinical, and imaging data according to clinical outcome
| Favorable Outcome (n = 12) | Unfavorable Outcome (n = 15) | P Value | |
|---|---|---|---|
| Age (year) | 46.4 ± 13.9 | 58.7 ± 15.2 | .034 |
| Sex (M/F) | 8/4 | 5/10 | n.s. |
| NIHSS score | 15 ± 4 | 21 ± 5 | <.01 |
| Serum glucose level (mg/dL) | 135.6 ± 38.1 | 136.7 ± 29.7 | n.s. |
| Core (mL) | 8.6 ± 7.8 | 19.8 ± 14.5 | .03 |
| TTP/CBV mismatch ratio (%) | 75.4 ± 19.8 | 55.8 ± 23 | .03 |
| Infarct volume (mL) | 11.3 ± 11.2 | 36.8 ± 15.7 | <.01 |
| Infarct growth (%) | 31.2 ± 28 | 90 ± 45 | <.01 |
| Time to IAT (min) | 61.2 ± 36.5 | 66.6 ± 35.9 | n.s. |
| Time to recanalization (min) | 338 ± 50 | 371 ± 36 | n.s |
| Recanalization rate (TIMI, 2–3) | 11/12 | 8/15 | .03 |
| Symptomatic hemorrhage | 1 | 1 | |
| Thrombolytic agent | n.s | ||
| UK | 6/17 | 11/17 | |
| rtPA | 6/10 | 4/10 | |
| ASPECTS | 9 | 8.6 | n.s. |
Note:—n.s. indicates not significant; UK, urokinase; IAT, intra-arterial thrombolysis; rtPA, recombinant tissue plasminogen activator; ASPECTS, Alberta Stroke Program Early CT Score.